Human Immunodeficiency Virus Book

http://www.fpnotebook.com/

Indinavir

Aka: Indinavir, Crixivan
  1. See Also
    1. Anti-Retroviral Therapy
    2. Protease Inhibitor
  2. Mechanism
    1. Protease Inhibitor
  3. Efficacy
    1. Very effective in combination with Zidovudine (AZT)
  4. Dosing
    1. Indinavir 600 mg PO tid ($360/month)
    2. Take on empty Stomach
      1. One hour before or 2 hours after a meal
      2. Concurrent food reduces concentration up to 80%
    3. Drink at least 1.5 Liters (50 oz) liquid per day
      1. Drink 150 ml water per hour for 3 hours after dose
      2. Avoids Nephrolithiasis and Interstitial Nephritis
  5. Adverse Effects
    1. See Protease Inhibitor for adverse effects attributed to the class
    2. Well tolerated
    3. Indirect Bilirubin elevation in 10% of patients
    4. Nephrolithiasis in 2-3% of patients
    5. Renal Insufficiency
    6. Alopecia
    7. Dry Skin
    8. Xerostomia
    9. Paronychia
    10. Gallstones
  6. Drug Interactions
    1. St. John's Wort
      1. May reduce Indinavir concentrations by 80%
      2. Piscitelli (2000) Lancet 355:547-8
  7. References
    1. (1998) Med Lett Drugs Ther 40(1041):115
    2. (2009) Treat Guidel Med Lett 7(78): 11-22
    3. Reust (2011) Am Fam Physician 83(12): 1443-51

Crixivan (C0701105)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D019469
English indinavir sulfate (Crixivan), crixivan, Crixivan
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Indinavir (C0376637)

Definition (NCI) A drug that interferes with the ability of a virus to make copies of itself.
Definition (MSH) A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
Definition (CSP) potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
Definition (NCI) A synthetic antiviral agent. Indinavir selectively inhibits human immunodeficiency virus (HIV) protease, an essential enzyme for replication and maturation of viral particles. HIV protease inhibition prevents the normal cleavage of gag-pol viral polyproteins, resulting in the release of immature, noninfectious virions and protection of healthy host cells. (NCI04)
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D019469
SnomedCT 108695003, 372529006
English Indinavir, indinavir, INDINAVIR, IDV, Indinavir [Chemical/Ingredient], Indinavir (product), Indinavir (substance)
Swedish Indinavir
Czech indinavir
Finnish Indinaviiri
Russian INDINAVIR, ИНДИНАВИР
Polish Indynawir
Japanese インジナァビル, インジナビル
Spanish indinavir (producto), indinavir (sustancia), indinavir, Indinavir
French Indinavir
German Indinavir
Italian Indinavir
Portuguese Indinavir
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Navigation Tree